-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ProQR Therapeutics (NASDAQ:PRQR) Forecasted to Post FY2022 Earnings of ($0.77) Per Share
ProQR Therapeutics (NASDAQ:PRQR) Forecasted to Post FY2022 Earnings of ($0.77) Per Share
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) – Cantor Fitzgerald lifted their FY2022 EPS estimates for ProQR Therapeutics in a research note issued to investors on Monday, August 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will post earnings per share of ($0.77) for the year, up from their prior forecast of ($0.84). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.83) per share. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2023 earnings at ($0.62) EPS.
Get ProQR Therapeutics alerts:A number of other brokerages have also recently weighed in on PRQR. HC Wainwright dropped their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research report on Monday, May 9th. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price objective for the company in a research note on Friday, August 12th. Chardan Capital lowered shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $5.00.
ProQR Therapeutics Price Performance
Shares of PRQR opened at $0.85 on Wednesday. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The stock has a market cap of $60.60 million, a PE ratio of -0.85 and a beta of 0.80. The firm has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $1.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93.Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of ProQR Therapeutics during the 2nd quarter worth approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $80,000. Monaco Asset Management SAM purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth approximately $82,000. Coastal Bridge Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $85,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of ProQR Therapeutics by 22.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 2,352 shares during the last quarter.
ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
See Also
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) – Cantor Fitzgerald lifted their FY2022 EPS estimates for ProQR Therapeutics in a research note issued to investors on Monday, August 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will post earnings per share of ($0.77) for the year, up from their prior forecast of ($0.84). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.83) per share. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2023 earnings at ($0.62) EPS.
ProQR治疗公司(纳斯达克:PRQR-GET评级)--坎托·菲茨杰拉德在8月15日星期一发给投资者的一份研究报告中上调了他们对ProQR治疗公司2022财年每股收益的估计。Cantor Fitzgerald分析师J.Kim现在预测,这家生物制药公司今年的每股收益将为0.77美元,高于此前预测的0.84美元。康托·菲茨杰拉德目前对该股的评级为“中性”。对ProQR治疗公司目前全年收益的普遍估计为每股0.83美元。Cantor Fitzgerald还发布了对ProQR治疗公司2023财年每股收益的估计为(0.62美元)。
A number of other brokerages have also recently weighed in on PRQR. HC Wainwright dropped their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research report on Monday, May 9th. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price objective for the company in a research note on Friday, August 12th. Chardan Capital lowered shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $5.00.
其他一些券商最近也加入了PRQR的行列。在5月9日星期一的一份研究报告中,HC Wainwright将ProQR治疗公司的股票目标价从4.00美元下调至2.00美元。雷蒙德·詹姆斯在8月12日星期五的一份研究报告中将ProQR治疗公司的股票从“市场表现”评级上调至“跑赢大盘”评级,并为该公司设定了2.00美元的价格目标。Chardan Capital在8月12日星期五的一份研究报告中将ProQR治疗公司的股票评级从“买入”下调至“中性”。最后,StockNews.com在5月9日星期一的一份研究报告中将ProQR治疗公司的股票从“卖出”评级上调为“持有”评级。五位分析师对该股的评级为持有,四位分析师对该公司股票的评级为买入。根据MarketBeat的数据,该公司目前的普遍评级为持有,平均目标价为5.00美元。
ProQR Therapeutics Price Performance
ProQR治疗药物性价比
Institutional Inflows and Outflows
机构资金流入和流出
A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of ProQR Therapeutics during the 2nd quarter worth approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $80,000. Monaco Asset Management SAM purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth approximately $82,000. Coastal Bridge Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $85,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of ProQR Therapeutics by 22.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 2,352 shares during the last quarter.
一些机构投资者最近增持或减持了该公司的股份。Virtu Financial LLC在第二季度购买了ProQR治疗公司的新股份,价值约4.8万美元。ProShare Advisors LLC在第四季度购买了ProQR治疗公司的新股份,价值约8万美元。摩纳哥资产管理公司SAM在第一季度购买了ProQR治疗公司的新股份,价值约82,000美元。Coastate Bridge Advisors LLC在第四季度购买了ProQR治疗公司价值约8.5万美元的新股份。最后,大和证券集团在第四季度将其持有的ProQR治疗公司股票的仓位提高了22.1%。大和证券集团(Daiwa Securities Group Inc.)目前持有这家生物制药公司13,017股股票,价值10.4万美元,该公司在上个季度又购买了2,352股。
ProQR Therapeutics Company Profile
ProQR治疗公司简介
(Get Rating)
(获取评级)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物制药公司,致力于发现和开发基于RNA的治疗遗传疾病的疗法。它主要开发正处于II/III期临床试验的sepofarsen,用于治疗Leber先天性黑发10病的照明试验;以及正在进行II/III期临床试验的ultevursen,用于治疗USH2A介导的视网膜色素变性和USHER综合征。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
- 免费获取StockNews.com关于ProQR治疗(PRQR)的研究报告
- 哪些半导体类股准备好迎接价格大幅波动?
- 尽管面临更广泛的经济挑战,矿商的收益仍在上涨
- Lowe‘s在第二季度零售报告中脱颖而出
- 安捷伦科技对Illumina证明了自己的价值
- 塔吉特的业绩上限零售类股的上行潜力
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProQR治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧